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Metallothioneins (MT) are ubiquitous, intracellular small proteins with high affinity for heavy metal ions. In the last decades, it was
shown that MT overexpression in a variety of cancers is associated with resistance to anticancer drugs and is combined with a poor
prognosis. In this prospective study, we examined the role of MT overexpression in melanoma patients as a prognostic factor for
progression and survival. Between 1993 and 2004, 3386 patients with primary cutaneous melanoma were investigated by using a
monoclonal antibody against MT on routinely fixed, paraffin-embedded tissues. In all, 1270 patients could be followed up for further
statistical analysis (Fisher’s exact test, Mantel–Haenszel w
2 test, Kaplan–Meier curves). The MT data of disease-free interval and
overall survival were compared univariately and multivariately in Cox regression analysis. Immunohistochemical overexpression of MT
in tumour cells of patients with primary melanoma (310 of 1270; 24.4%) was associated with a higher risk for progression (117 of
167; 70.1%) and reduced survival (80 of 110; 72.7%) of the disease (Po0.0001). Similarly, Kaplan–Meier curves gave highly significant
disadvantages for the MT-positive group. Univariate analysis (relative risk 7.4; 95% confidence interval (CI) 5.2–10.2; Po0.0001 for
progression; relative risk 7.1; 95% CI 4.7–10.9; Po0.0001 for survival), as well as multivariate analysis with other prognostic markers
resulted in MT overexpression as a highly significant and independent factor for prognosis in primary melanoma.
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Melanoma is one of the most aggressive neoplasms in humans and
its incidence is still increasing. As there is still no effective curative
treatment in patients with disseminated melanoma, it is important
to estimate the risk for progression in the individual patient,
preferably at the time point of primary diagnosis. Breslow tumour
thickness is still the best prognostic factor for this issue.
Notwithstanding, everyone is aware of patients with thick
melanoma, who never develop metastases, and patients with
‘low-risk melanomas’ (thinner than 1.0mm), who will show
tumour progression in subsequent years. Therefore, additional
factors reliably determining progression and survival would be of
great benefit.
Metallothioneins (MT) are a group of ubiquitous, intracellular,
low molecular weight proteins (approximately 6.5kDa) with about
30% consisting of cysteine residues and no aromatic amino acids.
They have a specific binding capacity for heavy metal ions of
group II such as zinc, copper or cadmium (Nath et al, 1988; Miles
et al, 2000; Nordberg and Nordberg, 2000). To date, four major
isoforms have been identified in mammals; the specific functional
roles of MT isoforms or molecular interaction are still not precisely
known. As far as we know, MT are involved in many physiological
and pathophysiological processes such as the intracellular storage,
transport and metabolism of heavy metal ions; they regulate
essential trace metal homeostasis and play a protective role in
heavy metal detoxification reactions (Miles et al, 2000; Simpkins,
2000). They can protect cells against UV-/ionic radiation (Hansen
et al, 1997; Hanada et al, 1998; Reeve et al, 2000) as well as
cytotoxic alkylating agents including chemotherapeutics (Chin
et al, 1993; Hishikawa et al, 1997; Okazaki et al, 1998; Sunada et al,
2005), modulate oxygen free radicals and nitric oxide and inhibit
apoptosis (Tsangaris and Tzortzatou-Stathopoulou, 1998). The
synthesis of MT is induced by group II heavy metal ions as well as
by endogenous factors such as glucocorticoids, cytokines (inter-
leukin (IL)-1 or IL-6, interferon g (IFNg), tumour necrosis factor a
(TNF-a)) or vitamin D3 (Karin et al, 1985; Karasawa et al, 1987;
Schroeder and Cousins, 1990; Sato and Sasaki, 1992; Nishimura
et al, 2000). There is also some evidence that inflammatory
stressors (e.g. heat-shock proteins, reactive oxygen species,
endotoxin, IL-1, IL-6) induce MT synthesis, which, subsequently,
is strongly chemotactic for inflammatory cells, for example, T cells
(Yin et al, 2005), and influences angiogenesis (Miyashita and Sato,
2005).
Although MT participate in the carcinogenic process, their use
as a potential marker for tumour differentiation or cell prolifera-
tion, as well as a marker of poor prognosis remains controversial
(Cherian et al, 2003; Theocharis et al, 2004). In the last decade,
several reports disclosed MT overexpression as a useful prognostic
factor for tumour progression and drug resistance in a variety of
cancers such as ovarian cancer (Surowiak et al, 2005), renal cell
carcinoma (Mitropoulos et al, 2005), breast cancer (Jin et al, 2004),
non-small-cell lung carcinomas (Dziegiel et al, 2004), acute
lymphoblastic leukaemia (Sauerbrey et al, 1994), pancreatic
carcinoma (Ohshio et al, 1996) or carcinoma of the gallbladder
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s(Shukla et al, 1998). Similar results could be found in smaller
retrospective studies in melanoma and nonmelanoma skin cancers
(Zelger et al, 1993, 1994; Rossen et al, 1997; Goldmann et al, 1998;
Sugita et al, 2001). In some other tumours such as colorectal and
bladder cancer, MT overexpression was not correlated with
increased malignancy (O ¨fner et al, 1994; Jasani and Schmid, 1997).
In 2003, our department published the data of a prospective
study on 520 melanoma patients, where we were able to show that
MT overexpression is a significant and independent marker for
poor prognosis and survival (Weinlich et al, 2003). In the present
study, we present an update of this prospective cohort 11 years
after initiation.
MATERIALS AND METHODS
Patients
This prospective study was started in 1993 at the Clinical
Department of Dermatology and Venerology, Innsbruck Medical
University, Austria. Up to the end of 2004, 3386 patients with a
histological diagnosis of cutaneous melanoma were enrolled, and
1270 patients could be evaluated for further statistical analysis.
Besides Breslow’s tumour thickness and Clark’s level, ulceration,
location of the primary tumour, age and gender were added for
statistical analysis. Measuring end points were the time when a
progression (lymph node and/or distant metastasis) was detected
and when the patients died due to widespread disease. In the vast
majority of our patients (more than 90%), a histopathological
verification of the progression was possible by excision of
metastases or biopsy of suspicious lesions before initiation of
further therapy modalities.
Histopathological analysis
Formalin-fixed and paraffin-embedded tissues from melanoma
patients were routinely stained with haematoxylin and eosin. For
immunohistochemical investigations, sections of 4mm were
mounted on chromgel-coated glass slides, deparaffinised in xylene,
rehydrated in a graded series of alcohol and rinsed in Tris buffer.
Endogenous peroxidase was blocked by means of sodium azide,
glucose and glucose-oxidase. The primary monoclonal MT mouse-
IgG1 antibody E9 (clone E9; Dako, Denmark), which reacts with
both human epitopes of MT I and II isoforms, was applied,
followed by a peroxidase-conjugated rabbit-anti-mouse antibody.
The enzyme reaction was developed in a freshly prepared solution
containing 3-amino-9-ethylcarbazole and 0.01% hydrogen per-
oxide. Then, the sections were counterstained with haematoxylin,
dehydrated, cleared in xylene and mounted with entellan (Evering
et al, 1990; Jasani and Elmes, 1991). In those cases, where we had
multiple blocks of tumour specimens, the immunohistochemical
labelling was performed in all of them.
The stained sections were independently assessed by two
independent dermatohistopathological observers by an eyeball
estimate (EH and MB) without prior knowledge of the clinical data.
Generally, a good correlation and reproducibility was obtained by
the two observers. In rare cases of disagreement (o5%), both
reporting colleges (EHþMB) sat together with the senior author
(BZ), who has established this technique previously (Zelger et al,
1993; Zelger et al, 1994; Weinlich et al, 2003), discussed the
findings and performed the final evaluation. Only tumour cells
staining well above the background level (faint labelling was
occasionally observed around strongly positive cells, most likely
due to antigen diffusion) were considered to be positive. Reactivity
of basal keratocytes, the proliferating epithelium of the follicular
bulb and ductal epithelium of eccrine and apocrine glands served
as a positive internal control.
The specimens were scored as negative if there was a complete
lack of MT-positive cells, and only a faint hue of reactivity
compared with positive internal controls or only a minor
component of up to 10% positive tumour cells. Reactivity of more
than 10% was interpreted as MT overexpression. The limiting
value of 10% was chosen to prevent false-positive results. On the
one hand, the physiological proliferation rate of normal tissues as
well as the reactivity of various forms of melanocytic naevi are
usually smaller than our cutoff level; on the other hand, a counting
of cells less than 10%, although perhaps sufficient enough, would
be more inexact to measure by an eyeball estimate. In most of the
MT-positive cases, the MT monoclonal antibody diffusely labelled
the majority of tumour cells (Figure 1).
Statistical analysis
The ascertained data were statistically analysed using an SPSS
statistical software (SPSS for Windows, version 12.0; SPSS Inc.,
Chicago, IL, USA). The correlation between the immunohisto-
chemical data (absence or presence of MT overexpression) was
compared with the clinicopathological data (the occurrence or not
of metastasis and/or death due to melanoma) using the two-tailed
Fisher’s exact test and the Mantel–Haenszel w
2 test. Kaplan–Meier
curves were used to estimate the progression and survival (Kaplan
and Meier, 1958). Odds ratios and 95% confidence intervals (CIs)
were calculated for all known prognostic factors for progression
and survival using Cox regression analysis, assuming proportional
hazards in a univariate as well as multivariate approach (Spiegel,
1990). A P-value of o0.05 was considered statistically significant
in every statistical analysis.
RESULTS
Between 1993 and 2004, 3386 patients were recruited for this study;
1270 of them could be evaluated for statistical analysis. According
to standard guidelines of the Austrian Society of Dermatology and
Venerology, the majority of low-risk melanoma patients were
followed up by their local dermatologist, but never had
dermatological control for follow-up at our department, which
was one of the criteria for inclusion into the statistical analysis. In
addition, only patients with at least 3 months of observation could
enter this study. So out of the 3386 recruited, 1226 patients had to
be dropped, because they were lost for follow-up (observation o3
months). The majority of the lost patients had low-risk melanomas
o1.0mm or in situ melanomas (n¼1167, 95%). An additional 890
patients had to be dropped out for the statistical analysis (in situ
melanomas). Within the rest of the group of 1270 statistically
evaluable patients (4in situ, X3 months, complete data set),
males and females were nearly balanced (51%/49%), and the
median age at the time of excision was 54 years (range 7–95 years).
Breslow tumour thickness varied between 0.12mm and a tumour
thickness of 30mm (median value 0.7mm, mean 1.3mm). Table 1
gives the characteristics of the 3386 patients included in the data
set and of those 1270 eligible for further analysis.
In 11 years of recruitment (median observation time 32
months), 167 of 1270 patients (13.1%) showed a progression of
their disease, and the median time to progression was 18.0 months
(mean value 26.0 months). In all, 110 of these patients (8.7%) died
because of the metastatic disease of melanoma. The median time
between detection of the first metastasis to death was 9.0 months
(mean 15.3 months), and the median time from primary diagnosis
of melanoma to death was 26.5 months (mean 35.1 months). None
of our patients with a tumour thickness o0.5mm developed
metastases.
The majority of patients who showed progression, that is, 117 of
167 (70.1%), and from those who died due to metastasis, that is, 80
of 110 (72.7%), showed an MT-overexpression of their primary
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smelanoma (Po0.001, w
2 test; Fisher’s exact test) (Table 2). Even in
patients with low-risk melanomas o1.0mm (846 of 1270), the
majority of those with progression, that is, 21 of 32 (65.6%,
w
2¼63.9; df¼1; Po0.001), and those who died, that is, 11 of 15
(73.3%, w
2¼39.0; df¼1; Po0.001), showed statistically significant
MT overexpression in their primary melanoma.
Figure 2 illustrates the progression and survival of melanoma
patients over a time period of 150 months estimated by the
Kaplan–Meier method. A total of 55.9% of the MT-positive
group, but only 10.9% of the MT-negative group developed
metastasis after 10 years of observation (Po0.0001); 44.1% of MT-
positive patients died within a period of 120 months due to
progression of melanoma, but only 6.8% of patients in the MT-
negative group (Po0.0001). According to the tumour node
metastasis (TNM) classification of the American Joint Committee
on Cancer 2001, we subdivided our patients into four groups
(o1.0mm, 1.01–2.0mm, 2.01–4.0mm, 44.01mm) with similar
results. Even in the group of low-risk melanomas thinner than
1.0mm, the prognosis for the MT-positive group was worse in
comparison with the MT-negative group. Figure 3 illustrates the
Kaplan–Meier curves for the progress-free interval; analogous
data for survival are not shown.
As the percentage of MT-positive melanomas was increasing
with higher Clark level and Breslow tumour thickness, we tried to
find out in a next step if MT overexpression is an independent
prognostic marker or just a parameter correlated with increasing
invasion level or tumour thickness. First, in a univariate Cox
proportional hazard model for disease progression, we found a
high significance of MT overexpression with an expected risk of
7.4 (95% CI 5.3–10.2). Metallothionein overexpression as well as
all groups of Breslow tumour thickness had P-values o0.001 in the
univariate analysis (Table 3). The patient’s data were also
calculated according to survival with similar results (expected risk
7.2, 95% CI 4.7–10.9; Po0.001).
Then, we adjusted the data of our patients according to other
prognostic factors such as Breslow tumour thickness, Clark level,
ulceration, tumour localisation, median age, gender and MT
overexpression in a multivariate Cox regression analysis to prove
the independence of these factors. The strongest significant
parameters for progression were tumour thickness and MT
overexpression; only Clark level V reached a significance of
Po0.05, and ulceration was not significant in our cohort (Table 4).
In the Cox regression model for survival, we found similar results
with two highly significant and independent parameters: MT
overexpression and Breslow tumour thickness.
For a further calculation, we adapted the regression analysis
with Breslow tumour thickness and age as continuous variables
(table not shown). In this model, tumour thickness (expected risk
1.13; 95% CI 1.1–1.2; Po0.001) and again MT overexpression
(expected risk 4.2; 95% CI 2.9–5.9; Po0.001) showed significant
results; Clark level IV (expected risk 5.9, 95% CI 1.8–19.3;
P¼0.003), Clark level V (expected risk 11.4, 95% CI 3.2–40.1;
Po0.001), ulceration (expected risk 1.5; 95% CI 1.0–2.2; P¼0.035)
as well as age (expected risk 1.0, 95% CI 1.01–1.03; P¼0.001) were
significant too. Analogous results could be found when we
calculated the same data in the analysis for survival, with only a
Figure 1 Metallothionein (MT)-positive (AþC) and MT-negative (BþD) melanomas with comparable tumour thickness (AþB 0.6mm CL III, CþD
1.0mm CL IV). The red colour of ACE (in AþC) indicates positivity, the brown colour (in D) represents melanin.
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ssmall difference; the localisation also reached a P-value o0.02
(expected risk 1.7, 95% CI 1.1–2.6).
DISCUSSION
Although there is still no effective treatment for disseminated
melanoma (stage IV), it is of great interest to estimate the risk for a
Table 1 Characteristics of melanoma patients 1993–2004
n¼3386 n¼1270
Number of
patients
(all patients
recruited 1993–
2004)
(4in situ, X3
months
observation)
Observation time (months)
Range 0–143 3–143
Mean 26.3 42.5
Median 13.0 32.0
Age (years)
Range 5–100 7–95
Mean 55.0 53.2
Median 57.0 54.0
Sex
Male 1589 (46.9%) 649 (51.1%)
Female 1797 (53.1%) 621 (48.9%)
Localisation
TANS 2228 (65.8%) 772 (60.8%)
Not TANS 1158 (34.2%) 498 (39.2%)
Ulceration
Present 157 (4.6%) 123 (9.7%)
Absent 3229 (95.4%) 1147 (90.3%)
Tumour thickness (mm)
In situ 1613 (47.6%)
o1.0 1291 (38.1%) 846 (66.6%)
1.01–2.0 263 (7.8%) 236 (18.6%)
2.01–4.0 124 (3.7%) 104 (8.2%)
44.01 95 (2.8%) 84 (6.6%)
Invasion level
CL I 1613 (47.6%)
CL II 257 (7.6%) 176 (13.9%)
CL III 1084 (32.0%) 736 (71.8%)
CL IV 376 (11.1%) 313 (24.6%)
CL V 56 (1.7%) 45 (3.5%)
CL¼Clark level; TANS¼thorax, upper arm, neck, scalp.
Table 2 Characteristics of MT overexpression in primary melanoma
MT-positive MT-negative
Number of melanoma 1270 310 24.40% 960 75.60%
Tumour thickness (mm)
o1.0 846 131 15.50% 715 84.50%
1.01–2.0 236 78 33.10% 158 66.90%
2.01–4.0 104 53 51.00% 51 49.00%
44.01 84 48 57.10% 36 42.90%
Progression (n¼167, 13.1%)
(w
2¼217.2, df¼1, Po0.001)
117 70.10% 50 29.90%
Death (n¼110, 8.7%)
(w
2¼152.4, df¼1, Po0.001)
80 72.70% 30 27.30%
MT¼metallothionein.
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Figure 2 Kaplan–Meier estimates for progression and survival in
melanoma patients.
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spossible progression as early as possible, at the time point of the
primary diagnosis of melanoma. Up to now, Breslow tumour
thickness is still the best prognostic marker in primary melanoma.
Over the preceding years, a wide variety of different prognostic
factors have been investigated: Clark level, tumour stage, growth
phase, ulceration, mitotic counts or tumour-infiltrating lympho-
cytes and many others. Most of these other prognostic markers
often derive their predictive value because of a direct or secondary
correlation with tumour thickness.
In this prospective study on 1270 melanoma patients with a
long time of follow-up, our statistical analysis was able to
document that MT overexpression is a potent, highly signifi-
cant and tumour thickness-independent factor, which helps to
assess and calculate the risk for subsequent progression.
This could be shown by several statistical methods like w
2 test,
Fisher’s exact test, Kaplan–Meier curves, as well as uni-
and multivariate Cox regression analysis. Our data are highly
significant in all used test systems, although 2116 out of
3386 initially included patients had to be dropped out, 95% of
them with melanomas o1.0mm, in situ melanomas or because
of too short a time of observation, due to our strict inclusion
criteria.
Our results can be interpreted from different aspects: on the one
hand, MT-negative melanoma thinner than 1.0mm practically
never cause any further problems. There were only three cases of
metastasis from an MT-negative melanoma thinner than 1.0mm
(three out of 1067 MT-negative cases, 0.28%); two of them had
distinct histological signs of regression. In our cohort, none of the
patients with tumours o0.5mm (591 patients with 54/9.1% MT
positive) developed metastasis in the subsequent years. This may
assure such patients of their good long-term outcome. So it should
be deliberated if MT-negative patients with melanomas thinner
than 1.0mm could be controlled more generously without
ultrasound- or X-ray-staging examinations. On the other hand,
MT-positive melanoma thinner than 1.0mm are at a higher risk of
developing metastasis and succumbing to their neoplastic disease.
In our study population, 5.3% of the patients in this ‘low-risk’
group (nine out of 170 MT-positive melanomas o1.0mm) showed
a progression of their disease; their relative risk is roughly
comparable to MT-negative melanoma with a thickness of 2.1–
4mm. This may be used to more carefully follow up these patients
and/or probably even serve as a tool to indicate and perform
sentinel lymph node biopsy. Moreover, this group of patients
could probably profit from adjuvant treatment.
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Figure 3 Kaplan–Meier curves for progression in melanoma patients in the different groups of Breslow tumour thickness.
Table 3 Univariate Cox proportional hazard model for disease progression and survival (tumour thickness/MT overexpression)
Progression Survival
n¼1270 Relative risk CI 95% P-value Relative risk CI 95% P-value
MT overexpression 7.36 5.28–10.25 o0.001 7.16 4.71–10.9 o0.001
Tumour thickness (mm)
o1.0 1 1
1.01–2.0 4.24 2.68–6.72 o0.001 5.44 2.9–10.19 o0.001
2.01–4.0 11.1 6.99–17.62 o0.001 11.56 6.03–22.16 o0.001
44.01 25.25 16.2–39.34 o0.001 35.06 19.49–63.07 o0.001
CI¼confidence interval; CL¼Clark level; MT¼metallothionein.
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sMetallothionein overexpression probably has an additional
value. In stage IV melanoma patients, anticancer drugs, as well
as irradiation therapy, are known to often show only a humbled
rate of clinical responses. These therapeutic failures may partially
be related to an enhanced MT overexpression in tumour cells,
although the involvement of MT in conferring resistance to
chemotherapeutics still remains under discussion (Chin et al, 1993;
Hishikawa et al, 1997; Okazaki et al, 1998; Cherian et al, 2003). As
a variety of endogenous factors (e.g. glucocorticosteroids, ILs,
IFNg, TNF-a) are involved in the induction of the synthesis of
intracellular MT, one may suggest that this may lead to an
overprotection of tumour cells against apoptosis, and, on the other
hand, supporting the metastatic behaviour of the tumour (Karin
et al, 1985; Karasawa et al, 1987; Nath et al, 1988; Schroeder and
Cousins, 1990; Sato and Sasaki, 1992; Tsangaris and Tzortzatou-
Stathopoulou, 1998; Miles et al, 2000; Nishimura et al, 2000).
In summary, our data confirm previous results of retrospective
and much smaller studies in melanoma, outlining that MT
overexpression is a useful and elegant tool for prognostication
(Zelger et al, 1993; Goldmann et al, 1998; Sugita et al, 2001). This
marker is highly significant and independent of tumour thickness
and already predictive in low-risk melanomas thinner than
1.0mm. These investigations by immunohistochemical labelling
on archival paraffin material are easy to assess and perform in
routine pathology and dermatopathology laboratories and the
costs are limited.
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